0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027
Published Date: August 2021
|
Report Code: QYRE-Auto-31H295
Home | Market Reports | Health | Pharmacy | Drugs & Medications
Global Irritable Bowel Syndrome with Diarrhea IBS D Drugs Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Code: QYRE-Auto-31H295
Report
August 2021
115 Pages
QYResearch
Region: Global, Japan, Europe, India, Southeast Asia, North America,
Description
Table of Content
Tables & Figures
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
Market Analysis and Insights: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market

In 2020, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size was US$ 1254.6 million and it is expected to reach US$ 2554.5 million by the end of 2027, with a CAGR of 10.7% during 2021-2027.

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Scope and Market Size
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2016-2027.

Segment by Type, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into

XIFAXAN
Viberzi
Lotronex
Other
Segment by Sales Channel, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is segmented into
Hospitals Pharmacy
Retail Pharmacy
Other
Regional and Country-level Analysis:
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Analysis
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2016-2021. Details included are company description, major business, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product introduction, recent developments, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales by region, type, application and by sales channel.
The major companies include:
Bausch Health
Allergan
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal Pharms
Pharscin Pharma
1 Study Coverage
1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type
1.2.2 XIFAXAN
1.2.3 Viberzi
1.2.4 Lotronex
1.2.5 Other
1.3 Market by Sales Channel
1.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Sales Channel
1.3.2 Hospitals Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Estimates and Forecasts
2.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2016-2027
2.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2016-2027
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2021 Versus 2027
2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2016-2027)
2.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2016-2021
2.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2022-2027)
2.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2016-2027)
2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2016-2021
2.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2022-2027)
2.4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2016-2027)
3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Manufacturers
3.1 Global Top Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers by Sales
3.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturer (2016-2021)
3.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers by Revenue
3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturer (2016-2021)
3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturer (2016-2021)
3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Manufacturer (2016-2021)
3.4 Competitive Landscape
3.4.1 Key Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Covered: Ranking by Revenue
3.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Concentration Ratio (CR5 and HHI) & (2016-2021)
3.4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution, Product Type
3.5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type
3.5.3 Date of International Manufacturers Enter into Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Bausch Health
4.1.1 Bausch Health Corporation Information
4.1.2 Bausch Health Description, Business Overview
4.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
4.1.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
4.1.5 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Product
4.1.6 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application
4.1.7 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Geographic Area
4.1.8 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel
4.1.9 Bausch Health Recent Development
4.2 Allergan
4.2.1 Allergan Corporation Information
4.2.2 Allergan Description, Business Overview
4.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
4.2.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
4.2.5 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Product
4.2.6 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application
4.2.7 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Geographic Area
4.2.8 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel
4.2.9 Allergan Recent Development
4.3 Sebela Pharmaceuticals
4.3.1 Sebela Pharmaceuticals Corporation Information
4.3.2 Sebela Pharmaceuticals Description, Business Overview
4.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
4.3.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
4.3.5 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Product
4.3.6 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application
4.3.7 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Geographic Area
4.3.8 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel
4.3.9 Sebela Pharmaceuticals Recent Development
4.4 Astellas Pharmaceuticals
4.4.1 Astellas Pharmaceuticals Corporation Information
4.4.2 Astellas Pharmaceuticals Description, Business Overview
4.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
4.4.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
4.4.5 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Product
4.4.6 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application
4.4.7 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Geographic Area
4.4.8 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel
4.4.9 Astellas Pharmaceuticals Recent Development
4.5 Amneal Pharms
4.5.1 Amneal Pharms Corporation Information
4.5.2 Amneal Pharms Description, Business Overview
4.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
4.5.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
4.5.5 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Product
4.5.6 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application
4.5.7 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Geographic Area
4.5.8 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel
4.5.9 Amneal Pharms Recent Development
4.6 Pharscin Pharma
4.6.1 Pharscin Pharma Corporation Information
4.6.2 Pharscin Pharma Description, Business Overview
4.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
4.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2016-2021)
4.6.5 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Product
4.6.6 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application
4.6.7 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Geographic Area
4.6.8 Pharscin Pharma Recent Development
5 Breakdown Data by Type
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2027)
5.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021)
5.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2022-2027)
5.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2027)
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2016-2027)
5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2016-2021)
5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2022-2027)
5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2016-2027)
5.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Selling Price (ASP) by Type (2016-2027)
6 Breakdown Data by Sales Channel
6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2016-2027)
6.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2016-2021)
6.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Sales Channel (2022-2027)
6.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2016-2027)
6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Sales Channel (2016-2027)
6.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2016-2021)
6.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Sales Channel (2022-2027)
6.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2016-2027)
6.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Selling Price (ASP) by Sales Channel (2016-2027)
7 North America
7.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2016-2027
7.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
7.2.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2027)
7.2.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2027)
7.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
7.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
8 Asia-Pacific
8.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2016-2027
8.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Region
8.2.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2016-2027)
8.2.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2016-2027)
8.3 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
8.4 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
9 Europe
9.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2016-2027
9.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
9.2.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2027)
9.2.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2027)
9.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
9.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
10 Latin America
10.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2016-2027
10.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
10.2.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2027)
10.2.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2027)
10.3 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
10.4 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
11 Middle East and Africa
11.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2027)
11.2.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2027)
11.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
11.4 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
12 Supply Chain and Sales Channel Analysis
12.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Supply Chain Analysis
12.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials and Upstream Suppliers
12.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Clients Analysis
12.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channel and Sales Model Analysis
12.4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
13 Market Dynamics
13.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
13.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Opportunities
13.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges
13.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
13.5 Porter’s Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
    Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2027
    Table 2. Major Manufacturers of XIFAXAN
    Table 3. Major Manufacturers of Viberzi
    Table 4. Major Manufacturers of Lotronex
    Table 5. Major Manufacturers of Other
    Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth by Application (US$ Million): 2021 VS 2027
    Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region (US$ Million): 2021 VS 2027
    Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2016-2021) & (K Units)
    Table 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2022-2027) & (K Units)
    Table 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2016-2021) & (US$ Million)
    Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
    Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturer (2016-2021) & (K Units)
    Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturer (2016-2021)
    Table 14. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturer (2016-2021) & (US$ Million)
    Table 15. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturer (2016-2021)
    Table 16. Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (2016-2021) & (USD/Unit)
    Table 17. Ranking of Global Top Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers by Revenue (US$ Million) in 2020
    Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
    Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs as of 2020)
    Table 20. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Manufacturing Base Distribution and Headquarters
    Table 21. Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Type
    Table 22. Date of International Manufacturers Enter into Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
    Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 24. Bausch Health Corporation Information
    Table 25. Bausch Health Description and Business Overview
    Table 26. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 27. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 28. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Product
    Table 29. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Application
    Table 30. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Geographic Area
    Table 31. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Sales Channel
    Table 32. Bausch Health Recent Development
    Table 33. Allergan Corporation Information
    Table 34. Allergan Description and Business Overview
    Table 35. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 36. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 37. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Product
    Table 38. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Application
    Table 39. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Geographic Area
    Table 40. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Sales Channel
    Table 41. Allergan Recent Development
    Table 42. Sebela Pharmaceuticals Corporation Information
    Table 43. Sebela Pharmaceuticals Description and Business Overview
    Table 44. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 45. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 46. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Product
    Table 47. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Application
    Table 48. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Geographic Area
    Table 49. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Sales Channel
    Table 50. Sebela Pharmaceuticals Recent Development
    Table 51. Astellas Pharmaceuticals Corporation Information
    Table 52. Astellas Pharmaceuticals Description and Business Overview
    Table 53. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 54. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 55. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Product
    Table 56. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Application
    Table 57. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Geographic Area
    Table 58. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Sales Channel
    Table 59. Astellas Pharmaceuticals Recent Development
    Table 60. Amneal Pharms Corporation Information
    Table 61. Amneal Pharms Description and Business Overview
    Table 62. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 63. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 64. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Product
    Table 65. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Application
    Table 66. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Geographic Area
    Table 67. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Sales Channel
    Table 68. Amneal Pharms Recent Development
    Table 69. Pharscin Pharma Corporation Information
    Table 70. Pharscin Pharma Description and Business Overview
    Table 71. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 72. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product
    Table 73. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Product
    Table 74. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Application
    Table 75. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) and Market Share by Geographic Area
    Table 76. Pharscin Pharma Recent Development
    Table 77. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021) & (K Units)
    Table 78. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2022-2027) & (K Units)
    Table 79. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2016-2021) & (US$ Million)
    Table 80. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
    Table 81. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2016-2021) & (K Units)
    Table 82. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Sales Channel (2022-2027) & (K Units)
    Table 83. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2016-2021) & (US$ Million)
    Table 84. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Sales Channel (2022-2027) & (US$ Million)
    Table 85. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021) & (K Units)
    Table 86. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2022-2027) & (K Units)
    Table 87. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 88. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2022-2027) & (US$ Million)
    Table 89. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021) & (K Units)
    Table 90. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2016-2021) & (K Units)
    Table 91. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2016-2021) & (K Units)
    Table 92. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2022-2027) & (K Units)
    Table 93. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2016-2027) & (US$ Million)
    Table 94. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2022-2027) & (US$ Million)
    Table 95. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021) & (K Units)
    Table 96. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2016-2021) & (K Units)
    Table 97. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021) & (K Units)
    Table 98. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2022-2027) & (K Units)
    Table 99. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 100. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2022-2027) & (US$ Million)
    Table 101. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021) & (K Units)
    Table 102. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2016-2021) & (K Units)
    Table 103. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021) & (K Units)
    Table 104. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2022-2027) & (K Units)
    Table 105. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 106. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2022-2027) & (US$ Million)
    Table 107. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021) & (K Units)
    Table 108. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2016-2021) & (K Units)
    Table 109. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021) & (K Units)
    Table 110. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2022-2027) & (K Units)
    Table 111. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021) & (US$ Million)
    Table 112. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2022-2027) & (US$ Million)
    Table 113. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021) & (K Units)
    Table 114. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2016-2021) & (K Units)
    Table 115. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials, Industry Status and Trend
    Table 116. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials and Upstream Suppliers
    Table 117. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Clients Status and Trend
    Table 118. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Clients
    Table 119. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
    Table 120. Key Drivers: Impact Analysis (2022-2027)
    Table 121. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
    Table 122. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Opportunities
    Table 123. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges
    Table 124. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
    Table 125. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Porter’s Five Forces Analysis
    Table 126. Research Programs/Design for This Report
    Table 127. Key Data Information from Secondary Sources
    Table 128. Key Data Information from Primary Sources
List of Figures
    Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Picture
    Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type in 2021 & 2027
    Figure 3. XIFAXAN Product Picture
    Figure 4. Viberzi Product Picture
    Figure 5. Lotronex Product Picture
    Figure 6. Other Product Picture
    Figure 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application in 2021 & 2027
    Figure 8. Hospitals Pharmacy Examples
    Figure 9. Retail Pharmacy Examples
    Figure 10. Other Examples
    Figure 11. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered
    Figure 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size, (US$ Million), 2016 VS 2021 VS 2027
    Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size 2016-2027 (US$ Million)
    Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2016-2027 (K Units)
    Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Market Share by Region: 2021 Versus 2027
    Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Region (2016-2027)
    Figure 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2016-2027)
    Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturer in 2020
    Figure 19. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
    Figure 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Type (2016-2027)
    Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Type (2016-2027)
    Figure 22. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
    Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Application (2016-2027)
    Figure 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Application (2016-2027)
    Figure 25. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
    Figure 26. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2016-2027 (US$ Million)
    Figure 27. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2021)
    Figure 28. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2021)
    Figure 29. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2016-2027 (US$ Million)
    Figure 30. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2016-2027)
    Figure 31. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2016-2027)
    Figure 32. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2021)
    Figure 33. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2021)
    Figure 34. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2016-2027 (US$ Million)
    Figure 35. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2027)
    Figure 36. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2027)
    Figure 37. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2021)
    Figure 38. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2021)
    Figure 39. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2016-2027 (US$ Million)
    Figure 40. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2027)
    Figure 41. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2021)
    Figure 42. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2021)
    Figure 43. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2021)
    Figure 44. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2016-2027 (US$ Million)
    Figure 45. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2027)
    Figure 46. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2027)
    Figure 47. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2021)
    Figure 48. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2021)
    Figure 49. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Supply Chain (Upstream and Downstream Market)
    Figure 50. Global Production Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Materials by Region in 2020
    Figure 51. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distribution Channels
    Figure 52. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Percentage 2016-2027: Indirect Sales VS Direct Sales
    Figure 53. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Percentage 2016-2027: Online Sales VS Offline Sales
    Figure 54. Porter's Five Forces Analysis
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation
    Figure 57. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$5900
This license allows only one user(purchaser of the report) to access the PDF.

Electronic (PDF)
$8850
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$11800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Leap India
SIMILAR REPORTS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Corticosteroid Nasal Spray Market Insights and Forecast to 2028
Global Corticosteroid Nasal Spray Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

120 Pages
Type: Report
Code: QYRE-Auto-37W6695
Fri Oct 21 00:00:00 UTC 2022

Add to Cart

Add to Cart

Global Chemotherapy Induced Acral Erythema Treatment Market Research Report 2022
Global Chemotherapy Induced Acral Erythema Treatment Market Research Report 2022

120 Pages
Type: Report
Code: QYRE-Auto-20J12409
Fri Oct 21 00:00:00 UTC 2022

Add to Cart

Global Chlordiazepoxide Hydrochloride Market Research Report 2022
Global Chlordiazepoxide Hydrochloride Market Research Report 2022

120 Pages
Type: Report
Code: QYRE-Auto-3N12505
Wed Oct 19 00:00:00 UTC 2022

Add to Cart